Analysis

Cytokinetics, Incorporated (CYTK) Stock Analysis

Cytokinetics, Incorporated investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to CYTK.

websiteCYTK/analysis/CYTK

Cytokinetics, Incorporated

Cytokinetics, Incorporated investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to CYTK.

Stock profile

Ticker

CYTK

Asset type

Stock

Market cap

$9.80B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Cytokinetics, Incorporated may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • CYTK primary listing
  • KK3A
  • A1W1KK
  • 1CYTK

Latest Cytokinetics, Incorporated news

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GL...

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Multinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ...

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Sh...

SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,...

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,1...

Research sections

Valuation

Review valuation context for Cytokinetics, Incorporated.

Future growth

Review future growth context for Cytokinetics, Incorporated.

Past performance

Review past performance context for Cytokinetics, Incorporated.

Financial health

Review financial health context for Cytokinetics, Incorporated.

Dividend

Review dividend context for Cytokinetics, Incorporated.

Management

Review management context for Cytokinetics, Incorporated.

Ownership

Review ownership context for Cytokinetics, Incorporated.

Other information

Review other information context for Cytokinetics, Incorporated.

Community

Review community context for Cytokinetics, Incorporated.